INTERCEPT Pathogen-Reduced PlasmaReduce Patient Risk of Transfusion Transmitted Infection
What is INTERCEPT Plasma?
The INTERCEPT Blood System for Plasma, pathogen reduction system, provides broad-spectrum reduction of pathogens and leukocytes, reducing the risks of transfusion-transmitted infection (TTI) from known and certain emerging pathogens, as well as transfusion-associated graft-versus-host disease (TA GvHD). INTERCEPT-treated plasma has a proven track record of safety and has demonstrated equivalent therapeutic efficacy to conventional plasma in clinical trials. Furthermore, the INTERCEPT treatment for plasma and platelets can occur on the same Illuminator platform for optimal efficiency.
Broad spectrum of pathogens inactivated by the INTERCEPT Blood System for Plasma1
DHBV (model for HBV)
BVDV (Model for HCV)
There is no pathogen inactivation process that has been shown to eliminate all pathogens. Certain non-enveloped viruses (e.g., HAV, HEV, B19 and poliovirus) and Bacillus cereus spores have demonstrated resistance to the INTERCEPT process. For a full list of pathogens, please refer to package inserts.